Russell Swerdlow on Gaining a Foothold: Amyloid Immunotherapy in Clinical Practice
COMMENT Since January, we have gone from about 20 clinic patients on leqembi to about 40. By the numbers, therefore, the rate of enrollment over the past four months has not clearly accelerated since the close of 2023. This might be a little misleading, as it is